Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Toronto-Dominion Bank — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.16B), while Toronto-Dominion Bank trades at $114.14 (market cap $186.61B). The key difference: Toronto-Dominion Bank is far larger — about 3.2× Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)'s market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and Toronto-Dominion Bank for 84 Days on average.
| TAK | TD | |
|---|---|---|
Market Cap | $58.16B | $186.61B |
Volume | 2,467,530 | 4,056,663 |
Sector | Health | Financials |
52-Week High | $19.05 | $124.80 |
52-Week Low | $13.23 | $78.32 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $86.04B | $559.39B |
Dividend Yield | 3.36% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TD stock trades at $114.04, down 3.5% today, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.98 versus $1.74 expected. The company announced a $10 billion share buyback program and is expanding its U.S. branch network. Revenue grew to $61.28 billion in 2025, with a net income margin of 24.88%.
The outlook is mixed: strong profitability and analyst buy ratings support upside, but bearish technicals and volatile cash flows pose risks. The stock's valuation appears reasonable with a P/E of 17.39. Key risks include execution of expansion plans and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
